Presence at the EuroPCR08 will highlight choice of different modalities
available on single integrated imaging platform.
SAN DIEGO, and BRUSSELS, Belgium, May 12 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the 1,000th worldwide placement of the newest s5 and s5i integrated imaging consoles since the formal launch in April of 2006. This announcement comes just prior to Volcano's participation in the EuroPCR 2008 Congress, to be held in Barcelona, Spain, from May 12-15th. During the PCR, Volcano will highlight the s5i integrated Imaging System, complete with two new functionality options, which enable high frequency rotational IVUS and FFR to operate on the same platform as Volcano's phased array IVUS catheters.
Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Reaching this milestone as quickly as we have is a clear indication of the clinical adoption of IVUS and FFR, and the competitiveness of our product. More and more physicians are using intravascular imaging to measure lesion significance and improve PCI technique. The ease of use and flexibility of our newest systems have been very well received. These new systems are gaining traction with both new IVUS users, as well as those who are looking to replace their legacy IVUS technology."
The newest Volcano s5i integrated system now available for evaluation
is the only imaging system that accommodates phased array IVUS, high
frequency rotational IVUS, an
|SOURCE Volcano Corporation|
Copyright©2008 PR Newswire.
All rights reserved